Novartis Ag (NVS) Return on Capital Employed (2009 - 2010)
Novartis Ag (NVS) posted Return on Capital Employed of 2.02% for Q1 2010, down 100.0% sequentially from 3415578.1% in Q4 2009, and down 2062512434.0% YoY from N/an in Q1 2009.
Novartis Ag (NVS) Return on Capital Employed (2009 - 2010) Analysis & Trends
Novartis Ag has reported Return on Capital Employed for 2 years, with the latest figure at 2.02% in Q1 2010.
- Quarterly Return on Capital Employed fell 2062512434.0% year-over-year to 2.02% in Q1 2010, while the trailing twelve-month figure through Mar 2010 was 2.02% (down 2062512434.0% YoY) and the FY2025 annual result came in at 22.24%, up 216.0% from the prior year.
- Return on Capital Employed slipped to 2.02% in Q1 2010 per NVS's latest filing, from 3415578.1% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20625126.35% in Q1 2009 and troughed at 2.02% in Q1 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2010 | 2.02% |
| Dec 31, 2009 | 3,415,578.10% |
| Sep 30, 2009 | 10,898,566.66% |
| Jun 30, 2009 | 7,525,404.55% |
| Mar 31, 2009 | 20,625,126.35% |